Form 4 Jounce Therapeutics, For: Aug 14 Filed by: Drapkin Kimberlee C
Last jounce therapeutics, inc earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: ir.jouncetx.com
| Impact snapshot | Event time: | JNCE | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
JNCE alerts
JNCE alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNCE alerts
High impacting Jounce Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
JNCE
News
- Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific OfficerGlobeNewswire
- Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual MeetingGlobeNewswire
- Jounce Therapeutics (JNCE) Investor Presentation - Slideshow [Seeking Alpha]Seeking Alpha
- Jounce Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/JNCE/price-target/">NASDAQ: JNCE</a>) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $20.00 price target on the stock.MarketBeat
- Jounce Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/JNCE/price-target/">NASDAQ: JNCE</a>) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $20.00 price target on the stock.MarketBeat
- More
JNCE
SEC Filings
- 4/16/21 - Form 4
- 4/5/21 - Form SC
- 3/31/21 - Form 4
- JNCE's page on the SEC website
- More